Thu, Dec 18, 2014, 7:13 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • until you understand that this represents aprx 6% of the float.,or 3% of total shares and that certain parties will soon approach owning a majority of the company.Sure it could be sold and going private may not happpen.GHDX is a rare bird indeed.Take note that the SP was pushed to near the years low after being up 25% most of the rest of the year to facilitate not only this ASR but a large purchase by insiders in recent trades.
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The buying last month was the Baker Brothers but this move has yielded no 5% SEC docs.I have a different take.The cap gains tax was paid for with this push down,.You can see it all the big holdings of the #$%$.Next year will be a min 50% gain if the co isnt sold or gone private

    • I wonder if that kind of taking majority command of a public company is legal in the US. It's too obvious, isn't it?!

    • Terry - take a look in the Oregonian online and review an article about Oregon Health Sciences University (OHSU) and their genomic tests for cancer. My concern is that the field of genomic testing is getting crowded. Will GHDX need to lower prices to stay competitive?

      Sentiment: Hold

      • 1 Reply to mdwhittier
      • I'm the trader in the family and my wife the scientist just flew to D.C.(Ill ask her)))

        I do see however ,this is a stripped down test,targeting ?what Cancers?
        Like trading there are numbers and probabilities, .and GHDX testing gives the best probabilities.
        Genomic Health specifically has targeted Colon and breast,and the juggernaut of health care cost
        -prostate

        article: "Under the FDA's system, drug approval requires a new years-long trial for each disease or type of tumor."

        jmho- this compassionate care from the University will need to do extensive trialing to match GHDX % probabilities./Insurance coverage

        No doubt there is competition and the OHSU story ,to this investor seems like clinical work years out....and money

        Genomic Health spends the most of anyone on R&D.
        Good Luck

 
GHDX
31.44+0.27(+0.87%)Dec 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.